Цитохром Р450-опосредованные взаимодействия моноклональных антител и малых молекул

Translated title of the contribution: CYTOCHROME P450-MEDIATED INTERACTIONS OF MONOCLONAL ANTIBODIES AND SMALL-MOLECULES DRUGS

Research output: Contribution to journalArticlepeer-review

Abstract

Immunologically active proteins such as interferons, interleukins (IL-1, IL-6, IL-10), various ligands (e.g., tumor necrosis factor alpha) which are produced in mammals in response to infectious or inflammatory processes can inhibit the activity of CYP450 enzymes. This interaction can result in an increase of CYP450-substrates levels and toxic effects of treatment. The use of cytokines as biological drugs also can affect the pharmacokinetics of coadministered medications. On the other hand, a decrease in the cytokines levels induced by monoclonal antibodies can restore liver enzyme activity that may be inhibited during infection or inflammation. This effect can lead to reduced effectiveness of the coadministered drugs that are CYP450 substrates due to the acceleration of drugs metabolism and decrease in their concentration. The article reviews the recent studies of CYP450-mediated interactions between monoclonal antibodies targeting various cytokines and small molecule drugs.
Translated title of the contributionCYTOCHROME P450-MEDIATED INTERACTIONS OF MONOCLONAL ANTIBODIES AND SMALL-MOLECULES DRUGS
Original languageRussian
Pages (from-to)43-50
JournalКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ
Issue number4
StatePublished - 2019

Keywords

  • monoclonal antibodies
  • SMALL MOLECULE DRUGS
  • DRUG-DRUG INTERACTION
  • CYTOCHROME P450
  • PROINFLAMMATORY CYTOKINES
  • CYTOKINE MODULATORS

Fingerprint

Dive into the research topics of 'CYTOCHROME P450-MEDIATED INTERACTIONS OF MONOCLONAL ANTIBODIES AND SMALL-MOLECULES DRUGS'. Together they form a unique fingerprint.

Cite this